{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'AECOPD is sudden worsening of COPD symptoms. Many studies have attempted to', 'measure the burden of bacterial or viral infections in patients with AECOPD, but very', 'few have investigated the presence of mixed viral and bacterial infections both in stable', 'COPD patients and during AECOPD.', '1.2.', 'Rationale for the study', 'Because the infectious aetiology of AECOPD has been suggested to vary according to', 'geographical region, the primary purpose of this study (which will be conducted in', 'several countries in Asia Pacific) is to evaluate the occurrence of potential bacterial and', 'viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.', 'Given the increasing and projected burden of COPD in the Asia Pacific region, this study', 'will also evaluate the frequency, severity and duration of AECOPD, as well as the impact', 'of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung', 'function.', 'In addition, both PCR and bacteriological methods will be used for characterisation and', '(quantification in some cases) of bacteria in sputum. To date, identification of bacteria', 'and assessment of bacterial load is done in the vast majority of cases by culture.', 'However, the few studies that have compared culture with PCR demonstrated that PCR is', 'more discriminatory at detecting typical airway bacteria [Curran, 2007;Singh, 2014].', 'Moreover, in a multi-centre study, PCR has the advantage that it can be performed on', 'stored sputum samples, and can therefore be done centrally, whereas culture has to be', 'performed on fresh sputum samples, which can lead to variable results due to variability', 'in testing methods between laboratories.', '2.', 'OBJECTIVES', '2.1.', 'Primary objective', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum of stable COPD patients and during AECOPD, using', 'respectively bacteriological methods and viral PCR, over the course of 1 year.', 'Refer to Section 9.1.1 for the definition of the primary endpoint.', '2.2.', 'Secondary objectives', 'To evaluate the concordance between PCR and bacteriological methods data in', 'sputum for potential bacterial pathogens.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum of stable COPD patients, by GOLD grade.', 'To estimate the proportion of potential bacterial and viral pathogens (overall and by', 'species) detected in sputum during AECOPD, by severity of AECOPD.', 'To estimate the incidence rate of all-cause AECOPD, overall and by GOLD grade.', '19-OCT-2018', '30', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'To describe the severity and duration of all-cause AECOPD, overall and by GOLD', 'grade.', 'To assess the impact of all-cause AECOPD on HRQOL.', 'To assess the impact of all-cause AECOPD on lung function.', 'To assess the impact of all-cause AECOPD on healthcare utilisation.', 'Refer to Section 9.1.2 for the definition of the secondary endpoints.', '2.3.', 'Tertiary objective(s)', 'To assess the use of EXACT-PRO for determining the end date of AECOPD.', 'To evaluate the load of bacterial and viral pathogen in stable COPD and during', 'AECOPD.', 'To collect biological specimens for future respiratory disease-related testing:', '- Aliquots of sputum samples for assay development and microbiome analysis at', 'stable visits and during exacerbation.', '-', 'Blood sampling for potential identification/quantification of biomarkers at Visit', '1 and Visit 3.', '-', 'Bacterial isolates for further strain characterisation.', 'Refer to Section 9.1.3 for the definition of the tertiary endpoints.', '19-OCT-2018', '31', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}